Hybio Pharmaceutical Liraglutide jekiseni rakabvumidzwa neUS FDA
2021.09——IWE Kutumira kwokutanga
2021.10——ANDA yakagamuchirwa zvakabudirira
2021.11——Liraglutide raw material yakanyoreswa neDMF
2023.10——Hybio Pharmaceuticals 'subsidiary, (hwaro hwekugadzirwa kwegadziriro) Bazi rePingshan, rakapedza ongororo yakaitwa neUnited States Food and Drug Administration (FDA) yezvazvino Good Manufacturing Practices (cGMP)
2023.11——Hybio Pharmaceuticals’subsidiary, (nheyo yeRaw material pharmaceutical) WuHan Branch, yakapedza ongororo yepanzvimbo neUnited States Food and Drug Administration (FDA) yezvino Good Manufacturing Practices (cGMP)
2023.12——Kambani yevabereki veHybio Pharmaceuticals, (yepakati peKutsvagisa nebudiriro) yakapedza kuongororwa pasaiti neUnited States Food and Drug Administration (FDA) yezvazvino Good Manufacturing Practices (cGMP)
2024.02——NFC mhinduro dzawanikwa dze liraglutide
2024.03—— Pedzisa kutenderera kwekupedzisira kweCRL mhinduro
2024.06--Batch rekutanga rejekiseni reLiraglutide rakaendeswa kuUnited States uye rakapedzisira ragamuchira mvumo kubva kuUS FDA.